PDCD1 and breast carcinoma: Lately, the histology-agnostic approval of ICB immunotherapy with pembrolizumab -an anti-programmed cell death-1 (PD-1) drug- for unresectable or metastatic dMMR or MSI-H solid tumors, increased the importance of assessing MMR status in breast cancer [61].